Abandoned. By the Side of the Road. In the Rain | GenomeWeb

The US National Institutes of Health has made a deal with Pfizer, AstraZeneca, and Eli Lilly to share "abandoned experimental drugs" with academic researchers, reports ScienceInsider's Jocelyn Kaiser. The hope, Kaiser says, is that researchers will be able to find new uses for the drugs. The companies will grant access to two dozen compounds that have passed safety studies, but were deemed ineffective for a specific purpose.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.